Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer

A real-world experience

Laura Pizzuti, Antonio Giordano, Andrea Michelotti, Marco Mazzotta, Clara Natoli, Teresa Gamucci, Claudia De Angelis, Elisabetta Landucci, Lucrezia Diodati, Laura Iezzi, Lucia Mentuccia, Agnese Fabbri, Maddalena Barba, Giuseppe Sanguineti, Paolo Marchetti, Silverio Tomao, Luciano Mariani, Ida Paris, Vito Lorusso, Simona Vallarelli & 30 others Alessandra Cassano, Francesca Airoldi, Armando Orlandi, Luca Moscetti, Domenico Sergi, Maria Giuseppina Sarobba, Giuseppe Tonini, Daniele Santini, Valentina Sini, Enzo Veltri, Angela Vaccaro, Laura Ferrari, Michele De Tursi, Nicola Tinari, Antonino Grassadonia, Filippo Greco, Andrea Botticelli, Nicla La Verde, Claudio Zamagni, Daniela Rubino, Enrico Cortesi, Valentina Magri, Giulia Pomati, Marina Cazzaniga, Maria Mancini, Silvia Carpano, Ruggero De Maria, Isabella Sperduti, Gennaro Ciliberto, Patrizia Vici

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8–16) and median overall survival was 24 months (95% CI, 17–30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2−, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.

Original languageEnglish
JournalJournal of Cellular Physiology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

exemestane
Confidence Intervals
Breast Neoplasms
Toxicity
Therapeutics
Neutropenia
Hormones
Disease-Free Survival
Neoplasm Metastasis
Survival
human ERBB2 protein
palbociclib
Neoplasms
Everolimus

Keywords

  • advanced breast cancer, hormonal therapy
  • endocrine resistance
  • palbociclib
  • real-world setting

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer : A real-world experience. / Pizzuti, Laura; Giordano, Antonio; Michelotti, Andrea; Mazzotta, Marco; Natoli, Clara; Gamucci, Teresa; De Angelis, Claudia; Landucci, Elisabetta; Diodati, Lucrezia; Iezzi, Laura; Mentuccia, Lucia; Fabbri, Agnese; Barba, Maddalena; Sanguineti, Giuseppe; Marchetti, Paolo; Tomao, Silverio; Mariani, Luciano; Paris, Ida; Lorusso, Vito; Vallarelli, Simona; Cassano, Alessandra; Airoldi, Francesca; Orlandi, Armando; Moscetti, Luca; Sergi, Domenico; Sarobba, Maria Giuseppina; Tonini, Giuseppe; Santini, Daniele; Sini, Valentina; Veltri, Enzo; Vaccaro, Angela; Ferrari, Laura; De Tursi, Michele; Tinari, Nicola; Grassadonia, Antonino; Greco, Filippo; Botticelli, Andrea; La Verde, Nicla; Zamagni, Claudio; Rubino, Daniela; Cortesi, Enrico; Magri, Valentina; Pomati, Giulia; Cazzaniga, Marina; Mancini, Maria; Carpano, Silvia; De Maria, Ruggero; Sperduti, Isabella; Ciliberto, Gennaro; Vici, Patrizia.

In: Journal of Cellular Physiology, 01.01.2018.

Research output: Contribution to journalArticle

Pizzuti, L, Giordano, A, Michelotti, A, Mazzotta, M, Natoli, C, Gamucci, T, De Angelis, C, Landucci, E, Diodati, L, Iezzi, L, Mentuccia, L, Fabbri, A, Barba, M, Sanguineti, G, Marchetti, P, Tomao, S, Mariani, L, Paris, I, Lorusso, V, Vallarelli, S, Cassano, A, Airoldi, F, Orlandi, A, Moscetti, L, Sergi, D, Sarobba, MG, Tonini, G, Santini, D, Sini, V, Veltri, E, Vaccaro, A, Ferrari, L, De Tursi, M, Tinari, N, Grassadonia, A, Greco, F, Botticelli, A, La Verde, N, Zamagni, C, Rubino, D, Cortesi, E, Magri, V, Pomati, G, Cazzaniga, M, Mancini, M, Carpano, S, De Maria, R, Sperduti, I, Ciliberto, G & Vici, P 2018, 'Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience', Journal of Cellular Physiology. https://doi.org/10.1002/jcp.27832
Pizzuti, Laura ; Giordano, Antonio ; Michelotti, Andrea ; Mazzotta, Marco ; Natoli, Clara ; Gamucci, Teresa ; De Angelis, Claudia ; Landucci, Elisabetta ; Diodati, Lucrezia ; Iezzi, Laura ; Mentuccia, Lucia ; Fabbri, Agnese ; Barba, Maddalena ; Sanguineti, Giuseppe ; Marchetti, Paolo ; Tomao, Silverio ; Mariani, Luciano ; Paris, Ida ; Lorusso, Vito ; Vallarelli, Simona ; Cassano, Alessandra ; Airoldi, Francesca ; Orlandi, Armando ; Moscetti, Luca ; Sergi, Domenico ; Sarobba, Maria Giuseppina ; Tonini, Giuseppe ; Santini, Daniele ; Sini, Valentina ; Veltri, Enzo ; Vaccaro, Angela ; Ferrari, Laura ; De Tursi, Michele ; Tinari, Nicola ; Grassadonia, Antonino ; Greco, Filippo ; Botticelli, Andrea ; La Verde, Nicla ; Zamagni, Claudio ; Rubino, Daniela ; Cortesi, Enrico ; Magri, Valentina ; Pomati, Giulia ; Cazzaniga, Marina ; Mancini, Maria ; Carpano, Silvia ; De Maria, Ruggero ; Sperduti, Isabella ; Ciliberto, Gennaro ; Vici, Patrizia. / Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer : A real-world experience. In: Journal of Cellular Physiology. 2018.
@article{5a3ccc17fabf4a239afeadb5ba27b467,
title = "Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience",
abstract = "Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31{\%} (95{\%} confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7{\%} (95{\%} CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95{\%} CI, 8–16) and median overall survival was 24 months (95{\%} CI, 17–30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2−, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.",
keywords = "advanced breast cancer, hormonal therapy, endocrine resistance, palbociclib, real-world setting",
author = "Laura Pizzuti and Antonio Giordano and Andrea Michelotti and Marco Mazzotta and Clara Natoli and Teresa Gamucci and {De Angelis}, Claudia and Elisabetta Landucci and Lucrezia Diodati and Laura Iezzi and Lucia Mentuccia and Agnese Fabbri and Maddalena Barba and Giuseppe Sanguineti and Paolo Marchetti and Silverio Tomao and Luciano Mariani and Ida Paris and Vito Lorusso and Simona Vallarelli and Alessandra Cassano and Francesca Airoldi and Armando Orlandi and Luca Moscetti and Domenico Sergi and Sarobba, {Maria Giuseppina} and Giuseppe Tonini and Daniele Santini and Valentina Sini and Enzo Veltri and Angela Vaccaro and Laura Ferrari and {De Tursi}, Michele and Nicola Tinari and Antonino Grassadonia and Filippo Greco and Andrea Botticelli and {La Verde}, Nicla and Claudio Zamagni and Daniela Rubino and Enrico Cortesi and Valentina Magri and Giulia Pomati and Marina Cazzaniga and Maria Mancini and Silvia Carpano and {De Maria}, Ruggero and Isabella Sperduti and Gennaro Ciliberto and Patrizia Vici",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/jcp.27832",
language = "English",
journal = "Journal of cellular and comparative physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer

T2 - A real-world experience

AU - Pizzuti, Laura

AU - Giordano, Antonio

AU - Michelotti, Andrea

AU - Mazzotta, Marco

AU - Natoli, Clara

AU - Gamucci, Teresa

AU - De Angelis, Claudia

AU - Landucci, Elisabetta

AU - Diodati, Lucrezia

AU - Iezzi, Laura

AU - Mentuccia, Lucia

AU - Fabbri, Agnese

AU - Barba, Maddalena

AU - Sanguineti, Giuseppe

AU - Marchetti, Paolo

AU - Tomao, Silverio

AU - Mariani, Luciano

AU - Paris, Ida

AU - Lorusso, Vito

AU - Vallarelli, Simona

AU - Cassano, Alessandra

AU - Airoldi, Francesca

AU - Orlandi, Armando

AU - Moscetti, Luca

AU - Sergi, Domenico

AU - Sarobba, Maria Giuseppina

AU - Tonini, Giuseppe

AU - Santini, Daniele

AU - Sini, Valentina

AU - Veltri, Enzo

AU - Vaccaro, Angela

AU - Ferrari, Laura

AU - De Tursi, Michele

AU - Tinari, Nicola

AU - Grassadonia, Antonino

AU - Greco, Filippo

AU - Botticelli, Andrea

AU - La Verde, Nicla

AU - Zamagni, Claudio

AU - Rubino, Daniela

AU - Cortesi, Enrico

AU - Magri, Valentina

AU - Pomati, Giulia

AU - Cazzaniga, Marina

AU - Mancini, Maria

AU - Carpano, Silvia

AU - De Maria, Ruggero

AU - Sperduti, Isabella

AU - Ciliberto, Gennaro

AU - Vici, Patrizia

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8–16) and median overall survival was 24 months (95% CI, 17–30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2−, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.

AB - Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8–16) and median overall survival was 24 months (95% CI, 17–30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2−, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.

KW - advanced breast cancer, hormonal therapy

KW - endocrine resistance

KW - palbociclib

KW - real-world setting

UR - http://www.scopus.com/inward/record.url?scp=85058158145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058158145&partnerID=8YFLogxK

U2 - 10.1002/jcp.27832

DO - 10.1002/jcp.27832

M3 - Article

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

ER -